The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer.
Enrico Vasile
No relevant relationships to disclose
Nelide De Lio
No relevant relationships to disclose
Carla Cappelli
No relevant relationships to disclose
Luca Pollina
No relevant relationships to disclose
Niccola Funel
No relevant relationships to disclose
Aldo Sainato
No relevant relationships to disclose
Laura Ginocchi
No relevant relationships to disclose
Maurizio Lucchesi
No relevant relationships to disclose
Chiara Caparello
No relevant relationships to disclose
Sara Caponi
No relevant relationships to disclose
Vittorio Perrone
No relevant relationships to disclose
Francesco Pasqualetti
No relevant relationships to disclose
Fabio Caniglia
No relevant relationships to disclose
Stefano Signori
No relevant relationships to disclose
Salvatore Mazzeo
No relevant relationships to disclose
Carlo Greco
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Daniela Campani
No relevant relationships to disclose
Franco Mosca
No relevant relationships to disclose
Ugo Boggi
No relevant relationships to disclose